These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 15890524)
1. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Gadducci A; Cosio S; Conte PF; Genazzani AR Crit Rev Oncol Hematol; 2005 Aug; 55(2):153-66. PubMed ID: 15890524 [TBL] [Abstract][Full Text] [Related]
2. Salvage chemotherapy for epithelial ovarian carcinoma. Christian MC; Trimble EL Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S143-50. PubMed ID: 7835799 [TBL] [Abstract][Full Text] [Related]
3. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P; J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064 [TBL] [Abstract][Full Text] [Related]
5. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents. Ozols RF J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247 [TBL] [Abstract][Full Text] [Related]
6. Maintenance or consolidation therapy in advanced ovarian cancer. Pectasides D; Pectasides E Oncology; 2006; 70(5):315-24. PubMed ID: 17164587 [TBL] [Abstract][Full Text] [Related]
7. The use of paclitaxel and cisplatin in a patient with epithelial ovarian cancer and human immunodeficiency virus. Knox SN; Robinson JB; Im DD; Logan L; Rosenshein NB Gynecol Oncol; 2000 Jan; 76(1):118-22. PubMed ID: 10620453 [TBL] [Abstract][Full Text] [Related]
9. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011 [TBL] [Abstract][Full Text] [Related]
10. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169 [TBL] [Abstract][Full Text] [Related]
11. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma]. Zhao XD; Zhang Y; He SR; Yang L Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810 [TBL] [Abstract][Full Text] [Related]
12. Ovarian carcinoma: the role of chemotherapy. Thigpen JT; Vance RB; Lambuth BW Semin Oncol; 1988 Jun; 15(3 Suppl 3):16-23. PubMed ID: 3293214 [TBL] [Abstract][Full Text] [Related]
13. Rationale for maintenance or consolidation therapy in ovarian cancer. Markman M Clin Adv Hematol Oncol; 2003 Mar; 1(3):176-8. PubMed ID: 16224399 [TBL] [Abstract][Full Text] [Related]
14. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534 [TBL] [Abstract][Full Text] [Related]
15. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma]. Zhao XD; Zhang Q; Zhang Y Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882 [TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel. Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790 [TBL] [Abstract][Full Text] [Related]
17. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Grossi F; Aita M; Follador A; Defferrari C; Brianti A; Sinaccio G; Belvedere O Oncologist; 2007 Apr; 12(4):451-64. PubMed ID: 17470688 [TBL] [Abstract][Full Text] [Related]
18. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A; J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330 [TBL] [Abstract][Full Text] [Related]
19. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Stathopoulos GP; Malamos NA; Aravantinos G; Rigatos S; Christodoulou Ch; Stathopoulos J; Skarlos D Cancer Chemother Pharmacol; 2007 Jun; 60(1):123-8. PubMed ID: 17111119 [TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ; J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]